Johnson & Johnson’s single-dose COVID-19 vaccine after six U.S. recipients developed a rare disorder involving blood clots.The U.S.
Food and Drug Administration and the U.S. Centers for Disease Control and Prevention said in a joint statement on Tuesday that the pause has been recommended “out of an abundance of caution” Johnson & Johnson vaccine under review in Europe after blood clot reports The New York Times was first to report the suspension, citing officials briefed on the decision.“Right now, these adverse events appear to be extremely rare,” the FDA wrote on Twitter.